216 related articles for article (PubMed ID: 12622416)
21. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis.
Gal A; Sjöblom T; Fedorova L; Imreh S; Beug H; Moustakas A
Oncogene; 2008 Feb; 27(9):1218-30. PubMed ID: 17724470
[TBL] [Abstract][Full Text] [Related]
22. Ubiquitin-dependent regulation of TGFbeta signaling in cancer.
Izzi L; Attisano L
Neoplasia; 2006 Aug; 8(8):677-88. PubMed ID: 16925950
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of farnesyltransferase increases TGFbeta type II receptor expression and enhances the responsiveness of human cancer cells to TGFbeta.
Adnane J; Bizouarn FA; Chen Z; Ohkanda J; Hamilton AD; Munoz-Antonia T; Sebti SM
Oncogene; 2000 Nov; 19(48):5525-33. PubMed ID: 11114730
[TBL] [Abstract][Full Text] [Related]
24. Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling.
Ge R; Rajeev V; Subramanian G; Reiss KA; Liu D; Higgins L; Joly A; Dugar S; Chakravarty J; Henson M; McEnroe G; Schreiner G; Reiss M
Biochem Pharmacol; 2004 Jul; 68(1):41-50. PubMed ID: 15183116
[TBL] [Abstract][Full Text] [Related]
25. TGFβ: A player on multiple fronts in the tumor microenvironment.
Caja F; Vannucci L
J Immunotoxicol; 2015; 12(3):300-7. PubMed ID: 25140864
[TBL] [Abstract][Full Text] [Related]
26. Escaping from the TGFbeta anti-proliferative control.
Seoane J
Carcinogenesis; 2006 Nov; 27(11):2148-56. PubMed ID: 16698802
[TBL] [Abstract][Full Text] [Related]
27. beta-Catenin and TGFbeta signalling cooperate to maintain a mesenchymal phenotype after FosER-induced epithelial to mesenchymal transition.
Eger A; Stockinger A; Park J; Langkopf E; Mikula M; Gotzmann J; Mikulits W; Beug H; Foisner R
Oncogene; 2004 Apr; 23(15):2672-2680. PubMed ID: 14755243
[TBL] [Abstract][Full Text] [Related]
28. Transforming growth factor beta induces apoptosis through repressing the phosphoinositide 3-kinase/AKT/survivin pathway in colon cancer cells.
Wang J; Yang L; Yang J; Kuropatwinski K; Wang W; Liu XQ; Hauser J; Brattain MG
Cancer Res; 2008 May; 68(9):3152-60. PubMed ID: 18451140
[TBL] [Abstract][Full Text] [Related]
29. TGF-beta signaling and its targeted therapy in gastrointestinal cancers.
Gotovac JR; Fujihara KM; Phillips WA; Clemons NJ
Discov Med; 2018 Sep; 26(142):103-112. PubMed ID: 30399328
[TBL] [Abstract][Full Text] [Related]
30. Raf and RhoA cooperate to transform intestinal epithelial cells and induce growth resistance to transforming growth factor beta.
Du J; Jiang B; Coffey RJ; Barnard J
Mol Cancer Res; 2004 Apr; 2(4):233-41. PubMed ID: 15140945
[TBL] [Abstract][Full Text] [Related]
31. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
32. Transforming growth factor β signaling regulates the invasiveness of normal mammary epithelial cells and the metastasis formation of tumor cells.
Vafaizadeh V; Graab U; Darvishi T; Machado R; Groner B
Horm Mol Biol Clin Investig; 2012 Jun; 10(1):227-39. PubMed ID: 25436679
[TBL] [Abstract][Full Text] [Related]
33. TGFβ Signaling in the Tumor Microenvironment.
Goulet CR; Pouliot F
Adv Exp Med Biol; 2021; 1270():89-105. PubMed ID: 33123995
[TBL] [Abstract][Full Text] [Related]
34. The role for transforming growth factor-beta (TGF-beta) in human cancer.
Gold LI
Crit Rev Oncog; 1999; 10(4):303-60. PubMed ID: 10654929
[TBL] [Abstract][Full Text] [Related]
35. TGF-β signaling pathway: Therapeutic targeting and potential for anti-cancer immunity.
Ali S; Rehman MU; Yatoo AM; Arafah A; Khan A; Rashid S; Majid S; Ali A; Ali MN
Eur J Pharmacol; 2023 May; 947():175678. PubMed ID: 36990262
[TBL] [Abstract][Full Text] [Related]
36. LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells.
Lu Z; Lam KS; Wang N; Xu X; Cortes M; Andersen B
Oncogene; 2006 May; 25(20):2920-30. PubMed ID: 16331278
[TBL] [Abstract][Full Text] [Related]
37. TGFβ overrides HNF4α tumor suppressing activity through GSK3β inactivation: implication for hepatocellular carcinoma gene therapy.
Cozzolino AM; Alonzi T; Santangelo L; Mancone C; Conti B; Steindler C; Musone M; Cicchini C; Tripodi M; Marchetti A
J Hepatol; 2013 Jan; 58(1):65-72. PubMed ID: 22960426
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of transforming growth factor beta signaling reduces pancreatic adenocarcinoma growth and invasiveness.
Gaspar NJ; Li L; Kapoun AM; Medicherla S; Reddy M; Li G; O'Young G; Quon D; Henson M; Damm DL; Muiru GT; Murphy A; Higgins LS; Chakravarty S; Wong DH
Mol Pharmacol; 2007 Jul; 72(1):152-61. PubMed ID: 17400764
[TBL] [Abstract][Full Text] [Related]
39. The regulation of apoptosis by activin and transforming growth factor-beta in early neoplastic and tumorigenic ovarian surface epithelium.
Choi KC; Kang SK; Tai CJ; Auersperg N; Leung PC
J Clin Endocrinol Metab; 2001 May; 86(5):2125-35. PubMed ID: 11344217
[TBL] [Abstract][Full Text] [Related]
40. Raf plus TGFbeta-dependent EMT is initiated by endocytosis and lysosomal degradation of E-cadherin.
Janda E; Nevolo M; Lehmann K; Downward J; Beug H; Grieco M
Oncogene; 2006 Nov; 25(54):7117-30. PubMed ID: 16751808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
